Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathryn Rankin

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2009
Multiple Histology Phase II TrialsMichael Leblanc, Cathryn Rankin, John Crowley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Obesity is an independent prognostic variable in colon cancer survivorsFrank A Sinicrope, Nathan R Foster, Daniel J Sargent, et al.
Investigational New Drugs|May 11, 2002
Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology GroupG Thomas Budd, Cathryn Rankin, Laura F Hutchins, et al.
Cancer|July 14, 2011
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomasMargaret von Mehren, Cathryn Rankin, John R Goldblum, et al.
Investigational New Drugs|May 11, 2002
Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group studySarah A Taylor, Cathryn Rankin, Jeannette J Townsend, et al.
Cancer|July 23, 2003
High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesotheliomaSusan M Talbot, Cathryn Rankin, Robert N Taub, et al.
Journal of Neuro-Oncology|January 5, 2008
A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149)Lode J Swinnen, Cathryn Rankin, Hetty Carraway, et al.
American Journal of Hematology|August 19, 2007
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)Stephen H Petersdorf, Cathryn Rankin, David R Head, et al.
Lung Cancer (Amsterdam, Netherlands)|November 17, 2007
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)Sujith R Kalmadi, Cathryn Rankin, Michael J Kraut, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Syma Iqbal, Cathryn Rankin, Heinz-Josef Lenz, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2009
Multiple Histology Phase II TrialsMichael Leblanc, Cathryn Rankin, John Crowley
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Obesity is an independent prognostic variable in colon cancer survivorsFrank A Sinicrope, Nathan R Foster, Daniel J Sargent, et al.
Investigational New Drugs|May 11, 2002
Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology GroupG Thomas Budd, Cathryn Rankin, Laura F Hutchins, et al.
Cancer|July 14, 2011
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomasMargaret von Mehren, Cathryn Rankin, John R Goldblum, et al.
Investigational New Drugs|May 11, 2002
Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group studySarah A Taylor, Cathryn Rankin, Jeannette J Townsend, et al.
Cancer|July 23, 2003
High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesotheliomaSusan M Talbot, Cathryn Rankin, Robert N Taub, et al.
Journal of Neuro-Oncology|January 5, 2008
A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149)Lode J Swinnen, Cathryn Rankin, Hetty Carraway, et al.
American Journal of Hematology|August 19, 2007
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)Stephen H Petersdorf, Cathryn Rankin, David R Head, et al.
Lung Cancer (Amsterdam, Netherlands)|November 17, 2007
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)Sujith R Kalmadi, Cathryn Rankin, Michael J Kraut, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Syma Iqbal, Cathryn Rankin, Heinz-Josef Lenz, et al.
Pageof 2